MDL-001: an Oral, Direct-Acting Universal Antiviral for Influenza-Like Illness (ILI) and Chronic Hepatitis

MDL-001 is the first broad-spectrum oral antiviral demonstrating in vivo efficacy against multiple RNA viruses, including influenza, RSV, SARS-CoV-2, and hepatitis B/C, with nanomolar potency.

• Why it matters: Addressing the global burden of diverse viral infections requires effective treatments that target multiple viruses simultaneously, filling a critical gap in current antiviral options.
• What they did: Researchers evaluated MDL-001 through in vitro potency tests and in vivo efficacy studies in animal models, showing comparable or superior performance to existing therapies across various viruses.
• The result: The compound exhibited strong antiviral activity, favorable pharmacokinetics, and safety profiles, supporting its advancement as a clinical candidate for universal influenza-like illness and hepatitis treatments.